Last reviewed · How we verify
Continuous Pramlintide infusion
At a glance
| Generic name | Continuous Pramlintide infusion |
|---|---|
| Also known as | pramlintide |
| Sponsor | University Diabetes & Endocrine Consultants |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Amylin-Induced Migraine Attacks Without Aura (NA)
- Hypersensitivity to Amylin in Post-Traumatic Headache (NA)
- Tailoring Obesity Treatment Trial (PHASE2, PHASE3)
- The Role of Amylin in Bone Metabolism (NA)
- Glucagon Counterregulation in Type 1 Diabetes (NA)
- Continuous Subcutaneous Infusion of Pramlintide and Insulin (PHASE4)
- Pramlintide Combined With Model Predictive Control Algorithm (NA)
- A Pilot Study of Continuous Subcutaneous Pramlintide Infusion Therapy in Patients With Type 1 Diabetes (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: